surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университет10.34822/2304-9448-2022-4-13-20surgumed-592Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНА. ОБЗОР ЛИТЕРАТУРЫCLINICAL MEDICINE. REVIEWSВОЗМОЖНОСТИ БИОЛОГИЧЕСКОЙ ТЕРАПИИ ПРИ ПСОРИАЗЕPOSSIBILITIES OF PSORIASIS BIOLOGICAL THERAPYhttps://orcid.org/0000-0002-9565-5469СарсурШади Х.Р.SarsurShadi Kh.R.

аспирант

E-mail: Dr.shadi.sarsour@gmail.com

 

Postgraduate

Dr.shadi.sarsour@gmail.comhttps://orcid.org/0000-0002-0621-5518РудневаНаталья СергеевнаRudnevaNatalya S.

кандидат медицинских наук, главный врач, доцент

E-mail: Natalya.Rudneva@8tularegion.ru

Candidate of Sciences (Medicine), Chief Medical Officer, Associate Professor

Natalya.Rudneva@8tularegion.ruТульский областной клинический кожно-венерологический диспансер, Тула; Кабардино-Балкарский государственный университет им. Х. М. Бербекова, НальчикРоссияTula Regional Clinical Dermatovenereological Dispensary, Tula; Kabardino-Balkarian State University named after H. M. Berbekov, NalchikRussian FederationТульский областной клинический кожно-венерологический диспансер, Тула; Тульский государственный университет, ТулаРоссияTula Regional Clinical Dermatovenereological Dispensary, Tula; Tula State University, TulaRussian Federation20222812202204 (54)1320Copyright © Сарсур Ш.Х., Руднева Н.С., 20222022Сарсур Ш.Х., Руднева Н.С.Sarsur S.K., Rudneva N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/592

Цель – анализ современных возможностей терапии псориаза генно-инженерными биологическими препаратами. Материалы и методы. Проанализированы метаанализы основных способов лечения псориаза среднетяжелого и тяжелого течения за последние 10 лет, наиболее эффективные и безопасные биологические препараты и особенности их назначения при различных сопутствующих состояниях. Результаты. Оценка результатов долгосрочного применения биологических препаратов показала их относительную безопасность. Потенциально более высокие риски злокачественности и инфицирования при биологической терапии требуют их назначения строго с учетом сопутствующих состояний. Доказательств неблагоприятного влияния биологических препаратов на течение сопутствующих заболеваний недостаточно.

The study aims to investigate the modern possibilities for psoriasis therapy using genetic engineering biological drugs. Materials and methods. The main meta-analyses on modern methods of treating moderate and severe psoriasis over the past 10 years have been examined. The most effective and safe biological drugs, as well as the features of their prescriptions for various concomitant conditions, have been identified. Results. Long-term use of biological drugs was evaluated and found to be relatively safe. Due to the potentially higher risks of malignancy and infection in biological therapy, biological drugs must be prescribed strictly according to concomitant conditions. There is insufficient evidence that biological drugs have a negative impact on the progression of concomitant diseases.

псориазгенно-инженерные препаратыбиологическая терапияинтерлейкиныингибиторы ФНО-αpsoriasisgenetic engineeringbiological therapyinterleukinsTNF-α inhibitorsReferencesФедеральная служба государственной статистики. URL: https://rosstat.gov.ru/folder/13721 (дата обращения: 12.10.2022).Федеральная служба государственной статистики. URL: https://rosstat.gov.ru/folder/13721 (дата обращения: 12.10.2022).Бакулев А. Л. Псориаз: клинические особенности, факторы риска и ассоциированные коморбидные состояния // Клинич. фармакология и терапия. 2019. Т. 28, № 1. С. 35–39.Бакулев А. Л. Псориаз: клинические особенности, факторы риска и ассоциированные коморбидные состояния // Клинич. фармакология и терапия. 2019. Т. 28, № 1. С. 35–39.Олисова О. Ю., Гаранян Л. Г. Эпидемиология, этиопатогенез и коморбидность при псориазе – новые факты // Рос. журн. кожных и венерич. болезней. 2017. Т. 20, № 4. С. 214–219.Олисова О. Ю., Гаранян Л. Г. Эпидемиология, этиопатогенез и коморбидность при псориазе – новые факты // Рос. журн. кожных и венерич. болезней. 2017. Т. 20, № 4. С. 214–219.Смольянникова В. А., Карамова А. Э. Роль IL-17А и нейтрофильных гранулоцитов в патогенезе псориаза // Архив патологии. 2020. Т. 82, № 1. С. 30–37.Смольянникова В. А., Карамова А. Э. Роль IL-17А и нейтрофильных гранулоцитов в патогенезе псориаза // Архив патологии. 2020. Т. 82, № 1. С. 30–37.Van der Fits L., Mourits S., Voerman J. S. A. et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis // The Journal of Immunology. 2014. Vol. 182, Is. 9. P. 5836–5845. DOI 10.4049/jimmunol.0802999.Van der Fits L., Mourits S., Voerman J. S. A. et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis // The Journal of Immunology. 2014. Vol. 182, Is. 9. P. 5836–5845. DOI 10.4049/jimmunol.0802999.Матушевская Е. В., Коновалова М. В. Патогенез и терапия псориаза и псориатического артрита // Клинич. дерматология и венерология. 2019. Т. 18, № 5. С. 634–643.Матушевская Е. В., Коновалова М. В. Патогенез и терапия псориаза и псориатического артрита // Клинич. дерматология и венерология. 2019. Т. 18, № 5. С. 634–643.Hawkes J. E., Chan T. C., Krueger J. G. Psoriasis Pathogenesis and the Development of Novel Targeted Immune Therapies // J Allergy Clin Immunol. 2017. Vol. 140, Is. 3. P. 645–653.Hawkes J. E., Chan T. C., Krueger J. G. Psoriasis Pathogenesis and the Development of Novel Targeted Immune Therapies // J Allergy Clin Immunol. 2017. Vol. 140, Is. 3. P. 645–653.Потекаев Н. Н., Круглова Л. С. Псориатическая болезнь. М. : МДВ, 2014. 264 с.Потекаев Н. Н., Круглова Л. С. Псориатическая болезнь. М. : МДВ, 2014. 264 с.Cheuk S., Schlums H., Gallais Serezal I. et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin // Immunity. 2017. Vol. 46, Is. 2. P. 287–300.Cheuk S., Schlums H., Gallais Serezal I. et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin // Immunity. 2017. Vol. 46, Is. 2. P. 287–300.Kim W. B., Jerome D., Yeung J. Diagnosis and Management of Psoriasis // Can Fam Physician. 2017. Vol. 63, Is. 4. P. 278–285.Kim W. B., Jerome D., Yeung J. Diagnosis and Management of Psoriasis // Can Fam Physician. 2017. Vol. 63, Is. 4. P. 278–285.Bagel J., Gold L. S. Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature // J Drugs Dermatol. 2017. Vol. 16, Is. 12. P. 1209–1222.Bagel J., Gold L. S. Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature // J Drugs Dermatol. 2017. Vol. 16, Is. 12. P. 1209–1222.Singh S. K., Singnarpi S. R. Safety and Efficacy of Methotrexate (0.3 mg/kg/week) versus a Combination of Methotrexate (0.15 mg/kg/week) with Cyclosporine (2.5 mg/kg/day) in Chronic Plaque Psoriasis: A Randomised Non-Blinded Controlled Trial // Indian J Dermatol Venereol Leprol. 2021. Vol. 87, Is. 2. P. 214–222. DOI 10.25259/IJDVL_613_19.Singh S. K., Singnarpi S. R. Safety and Efficacy of Methotrexate (0.3 mg/kg/week) versus a Combination of Methotrexate (0.15 mg/kg/week) with Cyclosporine (2.5 mg/kg/day) in Chronic Plaque Psoriasis: A Randomised Non-Blinded Controlled Trial // Indian J Dermatol Venereol Leprol. 2021. Vol. 87, Is. 2. P. 214–222. DOI 10.25259/IJDVL_613_19.Laws P. M., Young H. S. Current and Emerging Systemic Treatment Strategies for Psoriasis // Drugs. 2012. Vol. 72, Is. 14. P. 1867–1880.Laws P. M., Young H. S. Current and Emerging Systemic Treatment Strategies for Psoriasis // Drugs. 2012. Vol. 72, Is. 14. P. 1867–1880.Коротаева Т. В., Корсакова Ю. Л. Псориатичеcкий артрит: фокус на таргетную терапию // Эффектив. фармакотерапия. 2019. Т. 15, № 8. С. 42–50.Коротаева Т. В., Корсакова Ю. Л. Псориатичеcкий артрит: фокус на таргетную терапию // Эффектив. фармакотерапия. 2019. Т. 15, № 8. С. 42–50.Ellis A. G., Flohr C., Drucker A. M. Network Meta-Analyses of Systemic Treatments for Psoriasis: A Critical Appraisal // Br J Dermatol. 2019. Vol. 180, Is. 2. P. 282–288.Ellis A. G., Flohr C., Drucker A. M. Network Meta-Analyses of Systemic Treatments for Psoriasis: A Critical Appraisal // Br J Dermatol. 2019. Vol. 180, Is. 2. P. 282–288.Sbidian E., Chaimani A., Garcia-Doval I. et al. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis // Cochrane Database Syst Rev. 2017. Is. 12. P. CD011535.Sbidian E., Chaimani A., Garcia-Doval I. et al. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis // Cochrane Database Syst Rev. 2017. Is. 12. P. CD011535.Gordon K. B., Strober B., Lebwohl M. et al. Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results from Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials // Lancet. 2018. Vol. 392, Is. 10148. P. 650–661.Gordon K. B., Strober B., Lebwohl M. et al. Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results from Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials // Lancet. 2018. Vol. 392, Is. 10148. P. 650–661.Paul C., Griffiths C. E. M., van de Kerkhof P. C. M. et al. Ixekizumab Provides Superior Efficacy Compared with Ustekinumab over 52 Weeks of Treatment: Results from IXORA-S, a Phase 3 Study // J Am Acad Dermatol. 2019. Vol. 80, Is. 1. P. 70–79.E3.Paul C., Griffiths C. E. M., van de Kerkhof P. C. M. et al. Ixekizumab Provides Superior Efficacy Compared with Ustekinumab over 52 Weeks of Treatment: Results from IXORA-S, a Phase 3 Study // J Am Acad Dermatol. 2019. Vol. 80, Is. 1. P. 70–79.E3.Puig L., Lebwohl M., Bachelez H., Sobell J., Jacobson A. A. Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results from the Randomized, Double-Blind, Placeboand Active Comparator-Controlled Phase 3 AMAGINE-2 Trial // J Am Acad Dermatol. 2020. Vol. 82, Is. 2. P. 352–359.Puig L., Lebwohl M., Bachelez H., Sobell J., Jacobson A. A. Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results from the Randomized, Double-Blind, Placeboand Active Comparator-Controlled Phase 3 AMAGINE-2 Trial // J Am Acad Dermatol. 2020. Vol. 82, Is. 2. P. 352–359.Sawyer L. M., Cornic L., Levin L. A. et al. Long-Term Efficacy of Novel Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response // J Eur Acad Dermatol Venereol. 2019. Vol. 33, Is. 2. P. 355–366.Sawyer L. M., Cornic L., Levin L. A. et al. Long-Term Efficacy of Novel Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response // J Eur Acad Dermatol Venereol. 2019. Vol. 33, Is. 2. P. 355–366.Sawyer L. M., Malottki K., Sabry-Grant C. et al. Assessing the Relative Efficacy of Interleukin-17 and Interleukin-23 Targeted Treatments for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response // PLoS ONE. 2019. Vol. 14, Is. 8. P. e0220868.Sawyer L. M., Malottki K., Sabry-Grant C. et al. Assessing the Relative Efficacy of Interleukin-17 and Interleukin-23 Targeted Treatments for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response // PLoS ONE. 2019. Vol. 14, Is. 8. P. e0220868.Sbidian E., Chaimani A., Afach S. et al. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis // Cochrane Database Syst Rev. 2020. Is. 1. P. CD011535.Sbidian E., Chaimani A., Afach S. et al. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis // Cochrane Database Syst Rev. 2020. Is. 1. P. CD011535.Кунгуров Н. В., Кениксфест Ю. В., Гришаева Е. В., Кохан М. М. Клинический опыт применения препарата иксекизумаб в терапии пациентки с тяжелым псориазом и псориатическим артритом, резистентными к терапии // Лечащий врач. 2020. № 5. С. 42. DOI 10.26295/OS.2020.20.45.008.Кунгуров Н. В., Кениксфест Ю. В., Гришаева Е. В., Кохан М. М. Клинический опыт применения препарата иксекизумаб в терапии пациентки с тяжелым псориазом и псориатическим артритом, резистентными к терапии // Лечащий врач. 2020. № 5. С. 42. DOI 10.26295/OS.2020.20.45.008.Круглова Л. С., Хотко А. А., Помазанова М. Ю. Инновационный отечественный препарат – новая эра терапии больных псориазом // Клинич. дерматология и венерология. 2019. Т. 18, № 4. С. 479–485.Круглова Л. С., Хотко А. А., Помазанова М. Ю. Инновационный отечественный препарат – новая эра терапии больных псориазом // Клинич. дерматология и венерология. 2019. Т. 18, № 4. С. 479–485.Сердюкова Е. А., Цой А. Я. Эффективность терапии этанерцептом у пациентов с тяжелыми формами псориаза: клинические наблюдения // Клинич. дерматология и венерология. 2020. Т. 19, № 1. С. 75–81.Сердюкова Е. А., Цой А. Я. Эффективность терапии этанерцептом у пациентов с тяжелыми формами псориаза: клинические наблюдения // Клинич. дерматология и венерология. 2020. Т. 19, № 1. С. 75–81.Kaushik S. B., Lebwohl M. G. Psoriasis: Which Therapy for Which Patient. Psoriasis Comorbidities and Preferred Systemic Agents // J Am Acad Dermatol. 2019. Vol. 80, Is. 1. P. 27–40.Kaushik S. B., Lebwohl M. G. Psoriasis: Which Therapy for Which Patient. Psoriasis Comorbidities and Preferred Systemic Agents // J Am Acad Dermatol. 2019. Vol. 80, Is. 1. P. 27–40.Singh S., Taylor C., Kornmehl H., Armstrong A. W. Psoriasis and Suicidality: A Systematic Review and Meta-Analysis // J Am Acad Dermatol. 2017. Vol. 77, Is. 3. P. 425–440. E2.Singh S., Taylor C., Kornmehl H., Armstrong A. W. Psoriasis and Suicidality: A Systematic Review and Meta-Analysis // J Am Acad Dermatol. 2017. Vol. 77, Is. 3. P. 425–440. E2.Strober B., Gooderham M., de Jong E. M. G. J. et al. Depressive Symptoms, Depression, and the Effect of Biologic Therapy among Patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) // J Am Acad Dermatol. 2018. Vol. 78, Is. 1. P. 70–80.Strober B., Gooderham M., de Jong E. M. G. J. et al. Depressive Symptoms, Depression, and the Effect of Biologic Therapy among Patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) // J Am Acad Dermatol. 2018. Vol. 78, Is. 1. P. 70–80.Lee S. J., Tato M. C., Joyce-Saikh B. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability // Immunity. 2015. Vol. 43, Is. 4. P. 727–738. DOI 10.1016/j.immuni.2015.09.003.Lee S. J., Tato M. C., Joyce-Saikh B. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability // Immunity. 2015. Vol. 43, Is. 4. P. 727–738. DOI 10.1016/j.immuni.2015.09.003.Rodriguez-Zuniga M. J. M., Garcia-Perdomo H. A. Systematic Review and Meta-Analysis of the Association between Psoriasis and Metabolic Syndrome // J Am Acad Dermatol. 2017. Vol. 77, Is. 4. P. 657–666.E8.Rodriguez-Zuniga M. J. M., Garcia-Perdomo H. A. Systematic Review and Meta-Analysis of the Association between Psoriasis and Metabolic Syndrome // J Am Acad Dermatol. 2017. Vol. 77, Is. 4. P. 657–666.E8.Ikumi K., Odanaka M., Shime H. et al. Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice // J Invest Dermatol. 2019. Vol. 139, Is. 6. P. 1329–1338.E7. DOI 10.1016/j.jid.2019.01.029.Ikumi K., Odanaka M., Shime H. et al. Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice // J Invest Dermatol. 2019. Vol. 139, Is. 6. P. 1329–1338.E7. DOI 10.1016/j.jid.2019.01.029.Von Stebut E., Reich K., Thaci D. et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks // J Invest Dermatol. 2019. Vol. 139, Is. 5. P. 1054–1062.Von Stebut E., Reich K., Thaci D. et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks // J Invest Dermatol. 2019. Vol. 139, Is. 5. P. 1054–1062.Hjuler K. F., Bottcher M., Vestergaard C. et al. Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis // Am J Med. 2015. Vol. 128, Is. 12. P. 1325–1334.E2.Hjuler K. F., Bottcher M., Vestergaard C. et al. Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis // Am J Med. 2015. Vol. 128, Is. 12. P. 1325–1334.E2.Elnabawi Y. A., Dey A. K., Goyal A. et al. Coronary Artery Plaque Characteristics and Treatment with Biologic Therapy in Severe Psoriasis: Results from a Prospective Observational Study // Cardiovasc Res.2019. Vol. 115, Is. 4. P. 721–728.Elnabawi Y. A., Dey A. K., Goyal A. et al. Coronary Artery Plaque Characteristics and Treatment with Biologic Therapy in Severe Psoriasis: Results from a Prospective Observational Study // Cardiovasc Res.2019. Vol. 115, Is. 4. P. 721–728.Wu J. J., Guerin A., Sundaram M. et al. Cardiovascular Event Risk Assessment in Psoriasis Patients Treated with Tumor Necrosis Factor-Alpha Inhibitors Versus Methotrexate // J Am Acad Dermatol. 2017. Vol. 76, Is. 1. P. 81–90.Wu J. J., Guerin A., Sundaram M. et al. Cardiovascular Event Risk Assessment in Psoriasis Patients Treated with Tumor Necrosis Factor-Alpha Inhibitors Versus Methotrexate // J Am Acad Dermatol. 2017. Vol. 76, Is. 1. P. 81–90.Hu Y., Chen Z., Gong Y., Shi Y. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis // Clin Drug Investig. 2018. Vol. 38. P. 191–199.Hu Y., Chen Z., Gong Y., Shi Y. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis // Clin Drug Investig. 2018. Vol. 38. P. 191–199.Costanzo A., Malara G., Pelucchi C. et al. Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival // Dermatology. 2018. Vol. 234, No. 1–2. P. 1–12.Costanzo A., Malara G., Pelucchi C. et al. Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival // Dermatology. 2018. Vol. 234, No. 1–2. P. 1–12.Van den Reek J. M. P. A., Kievit W., de Jong E. M. G. J. Comment on “Drug Survival Analysis Is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis” // Actas Dermosifliogr. 2017. Vol. 108, Is. 7. P. 695–696.Van den Reek J. M. P. A., Kievit W., de Jong E. M. G. J. Comment on “Drug Survival Analysis Is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis” // Actas Dermosifliogr. 2017. Vol. 108, Is. 7. P. 695–696.Mourad A., Straube S., Armijo-Olivo S., Gniadecki R. Factors Predicting Persistence of Biologic Drugs in Psoriasis: A Systematic Review and Meta-Analysis // Br J Dermatol. 2019. Vol. 181, Is. 3. P. 450–458.Mourad A., Straube S., Armijo-Olivo S., Gniadecki R. Factors Predicting Persistence of Biologic Drugs in Psoriasis: A Systematic Review and Meta-Analysis // Br J Dermatol. 2019. Vol. 181, Is. 3. P. 450–458.Van der Schoot L. S., van den Reek J. M. P. A., Groenewoud J. M. M. et al. Female Patients Are Less Satisfied with Biological Treatment for Psoriasis and Experience More Side-Effects than Male Patients: Results from the Prospective BioCAPTURE Registry // J Eur Acad Dermatol Venereol. 2019. Vol. 33, Is. 10. P. 1913–1920.Van der Schoot L. S., van den Reek J. M. P. A., Groenewoud J. M. M. et al. Female Patients Are Less Satisfied with Biological Treatment for Psoriasis and Experience More Side-Effects than Male Patients: Results from the Prospective BioCAPTURE Registry // J Eur Acad Dermatol Venereol. 2019. Vol. 33, Is. 10. P. 1913–1920.Verstappen M. M. S., King Y., Watson K. D. et al. Anti-TNF Therapies and Pregnancy: Outcome of 130 Pregnancies in the British Society for Rheumatology Biologics Register // Ann Rheum Dis. 2015. Vol. 70, Is. 5. P. 823–826. DOI 10.1136/ard.2010.140822.Verstappen M. M. S., King Y., Watson K. D. et al. Anti-TNF Therapies and Pregnancy: Outcome of 130 Pregnancies in the British Society for Rheumatology Biologics Register // Ann Rheum Dis. 2015. Vol. 70, Is. 5. P. 823–826. DOI 10.1136/ard.2010.140822.European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines: Management of Hepatitis С Virus Infection // J Hepatol. 2017. Vol. 67, Is. 2. P. 370–398.European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines: Management of Hepatitis С Virus Infection // J Hepatol. 2017. Vol. 67, Is. 2. P. 370–398.European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series // J Hepatol. 2020. Vol. 73, Is. 5. P. 1170–1218.European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series // J Hepatol. 2020. Vol. 73, Is. 5. P. 1170–1218.Alpalhão M., Borges-Costa J., Filipe P. Psoriasis in HIV Infection: An Update // National Library of Medicine. 2019. Vol. 30, Is. 6. P. 596–604. DOI 10.1177/0956462419827673.Alpalhão M., Borges-Costa J., Filipe P. Psoriasis in HIV Infection: An Update // National Library of Medicine. 2019. Vol. 30, Is. 6. P. 596–604. DOI 10.1177/0956462419827673.Boehncke W. H., Schon M. P. Psoriasis // Lancet. 2015. Vol. 386, Is. 9997. P. 983–994. DOI 10.1016/S0140-6736(14)61909-7.Boehncke W. H., Schon M. P. Psoriasis // Lancet. 2015. Vol. 386, Is. 9997. P. 983–994. DOI 10.1016/S0140-6736(14)61909-7.

The authors declare that there are no conflicts of interest present.